Click on each heading to learn about the clinical trial phases.
Preclinical
| Assay/Test Method | Description | Results |
|---|---|---|
| MTT | Cytotoxic assay | Complete modulation |
| XTT | Cytotoxic assay | Complete modulation |
| Flow Cytometery | Flourescence | |
| Inhibition/efflux | ||
| -Rhodamine 123 | Complete Inhibition | |
| -Calcein | Complete Inhibition | |
| -In Vivo CDX 56 | Complete Inhibition |
Phase I Trials
Phase I in patients failing first line therapy using concurrent Doxorubicin at several dosage levels designed to determine maximum tolerable dose in combination with fixed dose of Doxorubicin and pharmacokinetic interaction.
Phase I with Paclitaxel in patients who had failed first line therapy, including Paclitaxel. Two additional patients entered on separate arm to study pharmacokinetic interaction.
Phase I study in combination with Paclitaxel and Carboplatin in unresectable NSCLC.
Phase I study in combination with Paclitaxel and Doxorubicin in advanced unresectable breast cancer.
Phase II Trials
Phase II study with high dose Cytosine Arabinoside and Daunorubicin in multiple relapsed or refractory AML
Phase II with Paclitaxel in various advanced relapsed cancers including GI, multiple myeloma, breast, SCLC,NSCLC,ovarian,prostate, cervical and head & neck.
Phase II Pharamcodynamic study of CBT-1® and Paclitaxel evaluating PGP inhibition in tumor and normal tissue conducted in collaboration with the NCI.
Phase III Trials
Placebo controlled randomized study of CBT-1® Paclitaxel and Carboplatin in NSCLC.